WASHINGTON, DC: U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla in the Oval Office of the White House as he announces a deal with Pfizer to lower drug prices on September 30, ...
LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good ...
The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S. President Donald Trump has already agreed to a similar pact ...
Hosted on MSN
Trump’s AstraZeneca Deal Echoes Pfizer Pact. Big Pharma’s Political Headaches Are Easing.
The press conference that President Donald Trump hosted in the Oval Office with the CEO of drugmaker AstraZeneca on Friday played like a rerun of the late September Oval Office press conference with ...
AstraZeneca PLC announced a deal with President Donald Trump that’s focused on lowering drug prices, in a move that would see the British drugmaker follow in the footsteps of Pfizer Inc. “Today, ...
The key drivers of increased investor interest in AstraZeneca are the strong performance of its oncology and cardiovascular franchises. For example, sales of Tagrisso, an EGFR inhibitor for the ...
LONDON, Oct 10 (Reuters) - Wall Street is looking to U.S. drugmaker Eli Lilly (LLY.N), opens new tab and Anglo-Swedish rival AstraZeneca (AZN.L), opens new tab as the potential next in line after ...
AstraZeneca has kept pace with drug rival Pfizer in striking a pricing deal with the Trump White House. AstraZeneca PLC announced a deal with President Donald Trump that's focused on lowering drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results